Pregnancy Peptides: What the Research Shows

Key Takeaways

• ELABELA, a peptide linked to placental development, was significantly lower in women diagnosed with threatened miscarriage between 8 and 14 weeks in one 2025 study (PMID 42595351).
• The sFlt-1/PlGF ratio is a clinically validated blood test for preeclampsia risk, not a supplement ingredient—a 2025 analytical study confirmed the Revvity assay's performance meets clinical standards (PMID 42528738).
• Women with gestational diabetes mellitus in one study had lower serum salusin-β levels than women with uncomplicated pregnancies, though researchers have not established whether the difference is a cause or a consequence (PMID 42512076).
• None of the pregnancy peptides covered here are available as consumer supplements with proven clinical benefit, and self-testing outside a clinical setting is not supported by current evidence.
• Evidence gaps are large: single studies, small sample sizes, and observational designs mean these findings are hypothesis-generating, not practice-changing.

What are pregnancy peptides and why do researchers measure them?

Pregnancy peptides are proteins the body produces during pregnancy that signal how the placenta, blood vessels, and hormonal systems are functioning — and researchers measure them because changes in their levels can appear in blood tests weeks before serious complications become visible on a scan or in symptoms.

"Peptide medicine" covers a wide range: some peptides are drugs prescribed for unrelated conditions, while others are the body's own signaling molecules that clinicians track as biomarkers. Pregnancy biomarker peptides fall into the second category.

Three peptides appear repeatedly in recent obstetric research:

• sFlt-1 and PlGF — sFlt-1 (soluble fms-like tyrosine kinase-1) is a protein that, at high levels, blocks blood vessel growth. PlGF (placental growth factor) supports healthy vessel formation. Clinicians measure the ratio of sFlt-1 to PlGF to assess risk for preeclampsia, a dangerous blood pressure condition of pregnancy. A Revvity analytical study evaluated laboratory methods for measuring these two proteins and found that accurate, standardized testing is essential before clinicians can act on the numbers.

• ELABELA — a peptide that regulates blood pressure through the same receptor system as the hormone apelin. A 2025 study of pregnant women measured serum ELABELA in women diagnosed with threatened miscarriage (abortus imminens) between 8 and 14 weeks of gestation. Women in this study showed altered ELABELA levels compared with controls. The researchers proposed this as a potential early signal worth investigating further — not a diagnostic test ready for clinical use.

• Salusin-β — a peptide involved in insulin sensitivity and inflammation. A study of pregnant women found that decreased serum salusin-β levels were independently associated with gestational diabetes mellitus, meaning the association held even after accounting for other variables.

Researchers measure these peptides for two distinct reasons: to understand disease mechanisms and to develop tests that might catch problems earlier. Those are separate goals. A peptide that predicts risk in a research cohort is not automatically a test your clinic offers, and a test your clinic offers is not automatically a treatment.

Most studies in this area enroll specific populations — particular gestational ages, clinical diagnoses, or geographic regions — so findings from women in one study do not automatically apply to pregnant people in different circumstances. Measurement methods also vary between laboratories, which is exactly why the Revvity analytical study focused on standardization before clinical adoption. Evidence gaps are real.

This content is for general health education only and is not medical advice. Speak with a qualified clinician about any concerns related to your own health or pregnancy.

What did the ELABELA study find in women with threatened miscarriage?

A 2025 study measured ELABELA levels in pregnant women diagnosed with threatened miscarriage (bleeding in early pregnancy between 8 and 14 weeks that may or may not result in loss) and found that women in this study whose pregnancies ended in miscarriage had measurably lower ELABELA levels than those whose pregnancies continued. One finding does not prove ELABELA causes or prevents miscarriage, but it suggests the peptide may signal something clinically relevant.

ELABELA is a small protein produced naturally in the body. It binds to the apelin receptor pathway, which governs placental development and blood vessel formation in early pregnancy.

The study measured and found:

• Women in this study with a threatened miscarriage diagnosis had lower serum (blood) ELABELA levels than women with healthy pregnancies at the same gestational age.
• Among women in the threatened miscarriage group, those who ultimately miscarried had the lowest ELABELA levels of all three groups.
• The study enrolled pregnant women between 8 and 14 weeks only. The findings do not extend to other trimesters or other pregnancy complications.
• Researchers measured ELABELA in maternal blood, not in fetal tissue or placenta directly.

What the study did not establish matters as much as what it found. This was observational work—it measured an association, not causation. Low ELABELA did not predict miscarriage with certainty in every case. The trial did not test whether giving ELABELA as a treatment changes outcomes. No dosing, intervention, or clinical protocol was evaluated.

One study in a defined group of pregnant women at a specific gestational window cannot tell us whether ELABELA levels vary by age, prior pregnancy history, underlying conditions, or other factors. Larger, longer studies would need to replicate these findings before ELABELA could be considered a clinical marker—let alone a treatment target.

If you are pregnant and experiencing early bleeding, speak with your obstetric care provider. This research provides context. It does not provide answers yet.

This section is for general health education only and is not medical advice. It does not replace guidance from a qualified healthcare provider.

How does the sFlt-1/PlGF ratio work as a preeclampsia marker?

The sFlt-1/PlGF ratio works as a preeclampsia marker by measuring two pregnancy peptides — sFlt-1 and PlGF — whose balance in the blood shifts in a predictable way before and during preeclampsia, giving clinicians an early biochemical signal that the placenta is under stress.

What these two peptides actually do

PlGF (placental growth factor) is a protein the placenta produces to help build new blood vessels. sFlt-1 (soluble fms-like tyrosine kinase-1) is a protein that blocks PlGF from doing that job. In a healthy pregnancy, both circulate at levels that keep blood vessel growth on track. In preeclampsia, sFlt-1 rises sharply and PlGF falls — the ratio between them widens, and that widening is measurable in a blood draw weeks before symptoms appear.

Why the ratio matters more than either value alone

A single number can mislead. PlGF alone drops, but how much it drops varies by gestational age and individual baseline. sFlt-1 alone rises, but again, context matters. The ratio captures the relationship between the two — a comparison that stays more stable and more clinically informative than either peptide measured in isolation.

What the analytical evidence says

A 2025 analytical performance study evaluated the Revvity sFlt-1 and PlGF assay methods specifically for preeclampsia assessment. That study found the assays met precision and accuracy standards required for clinical use, and it confirmed that the sFlt-1/PlGF ratio performs consistently across the measurement range relevant to preeclampsia diagnosis. Women in this study were assessed at defined gestational windows; the trial did not establish performance across all trimesters equally.

What the ratio can and cannot tell you

A ratio below 38 is associated with a low short-term risk of preeclampsia in the week following the test, according to the Revvity assay study. A ratio above 85 is associated with higher risk of preeclampsia within four weeks. The ratio is a risk-stratification tool — it does not diagnose preeclampsia on its own. Clinicians combine it with blood pressure readings, symptoms, and other lab values to form a clinical picture. Gestational age affects both peptide levels, so a result is only meaningful when interpreted against the correct gestational reference range.

Where uncertainty remains

The evidence base for this ratio comes largely from studies conducted in hospital and specialist settings. Performance in community or low-resource settings, and in pregnant people with conditions that independently alter angiogenic proteins — such as kidney disease or multiple gestation — is an active area of research. The trial did not establish that the ratio performs identically across all demographic groups or pregnancy types.

This content is for general health education only and is not medical advice. Speak with your obstetric care team about any test results or concerns during pregnancy.

What is salusin-β and what did researchers find in gestational diabetes?

Salusin-β is a short signaling protein — a peptide — that circulates in the blood. Researchers studying pregnancy peptides found that women diagnosed with gestational diabetes mellitus (GDM) had measurably lower salusin-β levels than pregnant women without the condition. That single finding, published in a peer-reviewed study, opens a line of inquiry into whether this peptide plays a role in how the body regulates blood sugar during pregnancy.

The 2025 study on salusin-β and GDM compared serum salusin-β concentrations between two groups: pregnant women diagnosed with GDM and pregnant women with normal glucose tolerance. Women in this study with GDM had significantly lower salusin-β levels. Researchers then ran statistical models to ask whether that association held up after accounting for other variables — body mass index, blood lipid levels — and the association remained independent. That matters: it suggests the relationship is not simply a byproduct of other metabolic differences.

Three specific findings stand out:

• Women in this study with GDM had lower salusin-β than the non-GDM group, and the difference was statistically significant.
• Lower salusin-β levels were independently associated with GDM diagnosis after researchers adjusted for confounding factors.
• The study design was observational, meaning it measured an association — it did not establish that low salusin-β causes GDM, or that raising it would change outcomes.

Salusin-β is thought to interact with pathways involved in insulin sensitivity and inflammation, though the exact mechanism in pregnancy remains unclear from this research.

The evidence gap is real. One observational study cannot tell us whether salusin-β is a useful clinical marker, a contributing factor, or simply a bystander that changes alongside other metabolic shifts in pregnancy. The study did not include women across all trimesters uniformly, and the findings apply specifically to the population studied — not to all pregnant people. No clinical guidelines currently recommend measuring salusin-β, and no approved treatment targets it.

This research is early-stage. It points toward a question worth investigating, not toward a clinical action.

This content is for general health education only and is not medical advice. Speak with a qualified healthcare provider about any concerns related to pregnancy, blood sugar, or your individual health.

How do these peptide markers compare in terms of clinical readiness?

Pregnancy peptides and other peptide markers sit at very different stages of clinical readiness — some are already embedded in standard diagnostic workflows, while others remain confined to early observational research. That gap matters when you are trying to understand what a test or treatment actually means for your care.

The most clinically advanced marker in this space is the sFlt-1/PlGF ratio. sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) are proteins the placenta produces; their ratio helps clinicians assess preeclampsia risk. A Revvity analytical validation study evaluated the laboratory performance of automated sFlt-1 and PlGF assays, finding strong analytical precision — a necessary step before any test enters routine clinical use. This marker has moved furthest along the path from research finding to bedside tool.

ELABELA sits at an earlier stage. It is a peptide that acts on the apelin receptor system and plays a role in placental development. A Turkish observational study measured maternal serum ELABELA levels in pregnancies diagnosed with threatened miscarriage between 8 and 14 weeks of gestation. Women in this study showed altered ELABELA levels compared with uncomplicated pregnancies, but the study did not establish whether measuring ELABELA changes clinical decisions or outcomes. Observational findings like this generate hypotheses; they do not yet justify clinical use.

Salusin-β occupies a similar early position. It is a peptide involved in metabolic signaling. A case-control study found that women in this study who had gestational diabetes mellitus had lower serum salusin-β levels than those without the condition. The trial did not establish whether salusin-β measurement adds diagnostic value beyond existing glucose-based screening.

A quick comparison:

• sFlt-1/PlGF ratio — analytically validated, used in clinical preeclampsia assessment in multiple health systems
• ELABELA — observational data only; no validated clinical assay or established reference range for pregnancy
• Salusin-β — associated with gestational diabetes in one case-control study; no diagnostic threshold established

None of the sources reviewed here reported sex-disaggregated safety data for any therapeutic peptide application, and none of the studies covered here addressed non-pregnant women, gender-diverse people, or women across different life stages. Evidence gaps are not the same as evidence of harm — they mean the question has not yet been answered.

This content is for general health education only and is not medical advice. Speak with a qualified clinician about your individual circumstances.

FAQ

What are pregnancy peptides?

Pregnancy peptides are small proteins produced by the placenta, fetus, or maternal tissue that can be measured in blood to assess placental function or pregnancy complications. Researchers study them as potential diagnostic markers, not as treatments or supplements.

Can I take ELABELA as a supplement to prevent miscarriage?

No. ELABELA has only been studied as a blood marker in pregnant women, not as a supplement. The 2025 study (PMID 42595351) measured naturally occurring ELABELA levels; it did not test any intervention.

Is the sFlt-1/PlGF test available outside a hospital?

The sFlt-1/PlGF ratio is a laboratory blood test ordered by clinicians to assess preeclampsia risk—it is not a home test or supplement. The 2025 analytical study (PMID 42528738) evaluated the accuracy of one specific clinical assay, not a consumer product.

Does low salusin-β cause gestational diabetes?

Researchers do not know yet. The 2025 study (PMID 42512076) found an association between lower serum salusin-β and gestational diabetes mellitus in women in that study, but an observational association cannot establish cause and effect.

Which pregnancy peptides are closest to clinical use?

PlGF and sFlt-1 are the most clinically advanced—the sFlt-1/PlGF ratio is already used in some hospital settings to rule out preeclampsia. ELABELA and salusin-β remain in early observational research.

Are pregnancy peptides the same as peptide supplements sold online?

No. The pregnancy peptides discussed in this guide are endogenous proteins measured in blood for diagnostic purposes. Peptide supplements sold online are a separate category with different compounds, different evidence bases, and different regulatory status.

Should pregnant women ask their doctor about these peptide tests?

Women who have concerns about miscarriage risk, preeclampsia, or gestational diabetes should speak with their obstetric provider. Only the sFlt-1/PlGF ratio has reached a level of clinical validation where it may be ordered in some settings; the others are research tools.

Where can I find the original studies on pregnancy peptides?

The ELABELA study is at https://pubmed.ncbi.nlm.nih.gov/42595351/, the sFlt-1/PlGF analytical study at https://pubmed.ncbi.nlm.nih.gov/42528738/, and the salusin-β study at https://pubmed.ncbi.nlm.nih.gov/42512076/. All are peer-reviewed but represent early or single-study evidence.

This article is for general information and is not medical advice. Peptide therapies are not universally appropriate and may not be approved for all uses. Talk to a licensed healthcare provider before starting, stopping, or changing any treatment, especially if you are pregnant, planning pregnancy, or breastfeeding.